Bank of New York Mellon
ERNA icon

Bank of New York Mellon’s Eterna Therapeutics ERNA Stock Holding History

Bank of New York Mellon’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7
Closed -$12K – 4490
2022
Q3 		$12K Hold
7
– – ﹤0.01% 4492
2022
Q2 		$26K Sell
7
-9
-56% -$64.6K ﹤0.01% 4466
2022
Q1 		$240K Hold
16
– – ﹤0.01% 4143
2021
Q4 		$487K Buy
16
+5
+45% +$272K ﹤0.01% 3824
2021
Q3 		$787K Buy
11
+1
+10% +$86.3K ﹤0.01% 3543
2021
Q2 		$1.29M Buy
+10
New +$1.44M ﹤0.01% 3260

Other funds holding ERNA

NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return
CPWM
Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $78.6B AUM 28.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Bank of New York Mellon's ERNA Position: Q4 2022 in Review

Bank of New York Mellon sold out of Eterna Therapeutics (ERNA) in Q4 2022, closing a stake of 7 shares — an estimated $12K sold.

Bank of New York Mellon first reported a position in ERNA in Q2 2021 and held it in 6 quarters. The position peaked at $1.29M in Q2 2021. 11 funds tracked by Wall St. Rank hold ERNA as of Q4 2022.

  • Bank of New York Mellon reported no remaining Eterna Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 7 Eterna Therapeutics shares in Q4 2022, an estimated $12K.
  • Bank of New York Mellon first reported a position in Eterna Therapeutics in Q2 2021 and held it in 6 quarters.
  • Bank of New York Mellon's Eterna Therapeutics position peaked at $1.29M in Q2 2021.
  • 11 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q4 2022.

Based on Bank of New York Mellon's 13F filing for Q4 2022, filed 14 Feb 2023.